Send to

Choose Destination
See comment in PubMed Commons below
J Control Release. 2001 Jul 6;74(1-3):295-302.

Development of the polymer micelle carrier system for doxorubicin.

Author information

Drug Research Department, Nippon Kayaku Co., Ltd., 3-31-12 Shimo, Kita-ku, 115-8588, Tokyo, Japan.


We show the result of pre-clinical study of NK911, a polymeric micelle carrier system for doxorubicin (DOX). The NK911 micelle carrier consists of polyethyleneglycol and conjugated doxorubicin-polyaspartic acid. It has high hydrophobic inner core, and therefore can entrap the sufficient amount of DOX. NK911 has a small particle size of about 40 nm in diameter that accumulates in tumor tissue by EPR effect showing much stronger activity than the free DOX. We plan to perform a clinical trial at National Cancer Center Hospital, Japan from 2001.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center